This study aims to estimate the COVID-19 vaccine acceptance and hesitancy among people living with HIV (PLWHA). A search for observational studies was conducted in five databases and preprinted literature. Summary estimates were pooled using a random effects model and meta-regression. Of 150 identified studies, 31 were eligible (18,550 PLWHA). The weighted prevalence of COVID-19 vaccine hesitancy overall was 29.07% among PLWHA (95%CI = 24.33-34.32; I² = 98%,) and that of vaccine acceptance was 68.66% (95%CI = 62.25-74.43; I² = 98%). Higher hesitancy prevalence was identified in low/lower-middle income countries (35.05; 95% CI = 19.38-54.78). The heterogeneity was explained by the risk of bias, region, and year of data collection. The findings conclude that the COVID-19 vaccine hesitancy rate remains high, especially in low-income countries. Evidence-informed interventions aimed at increasing COVID-19 vaccine acceptance at the national and individual levels ought to be designed to increase COVID-19 vaccine acceptance among PLWHA.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10461-024-04351-wDOI Listing

Publication Analysis

Top Keywords

covid-19 vaccine
24
vaccine acceptance
20
acceptance hesitancy
8
hesitancy people
8
people living
8
living hiv
8
vaccine hesitancy
8
i² 98%
8
covid-19
6
vaccine
6

Similar Publications

China witnessed an Omicron COVID-19 outbreak at the end of 2022. During this period, medical crowding and enormous pressure on the healthcare systems occurred, which might result in the occurrence of occupational burnout among healthcare workers (HCWs). This study aims to investigate the prevalence of occupational burnout and associated mental conditions, such as depressive symptoms, anxiety, PTSD symptoms, perceived social support, resilience, and mindfulness among HCWs of the Chinese mainland during the Omicron COVID-19 outbreak, and to explore the potential risk and protective factors influencing occupational burnout of HCWs.

View Article and Find Full Text PDF

Developing Countries Vaccine Manufacturers Network (DCVMN) is an alliance of vaccine developers, manufacturers, and marketing authorization holders (MAHs) from low- and middle-income countries (LMICs) that plays a vital role in ensuring equitable, inclusive, accountable, and timely access to affordable, high-quality vaccines in these countries. Besides research and development, this network promotes manufacturing and global supply chains for effective strengthening of regulatory and pharmacovigilance activities. Traditionally, vaccine safety surveillance systems in LMICs rely on spontaneous reporting.

View Article and Find Full Text PDF

Objective: To analyze the determinants for non-vaccination against COVID-19 in pregnant women in Belo Horizonte, Minas Gerais, Brazil.

Methods: An epidemiological study with a cross-sectional design was conducted using data from the project titled "Childbirth and Breastfeeding in Children of Mothers Infected by SARS-CoV-2," developed during the pandemic in the city of Belo Horizonte, Minas Gerais, Brazil.

Results: The study sample consisted of 360 pregnant women, of whom 77.

View Article and Find Full Text PDF

Dynamics and triggers of misinformation on vaccines.

PLoS One

January 2025

Centro Ricerche Enrico Fermi, Rome, Italy.

The Covid-19 pandemic has sparked renewed attention to the risks of online misinformation, emphasizing its impact on individuals' quality of life through the spread of health-related myths and misconceptions. In this study, we analyze 6 years (2016-2021) of Italian vaccine debate across diverse social media platforms (Facebook, Instagram, Twitter, YouTube), encompassing all major news sources-both questionable and reliable. We first use the symbolic transfer entropy analysis of news production time-series to dynamically determine which category of sources, questionable or reliable, causally drives the agenda on vaccines.

View Article and Find Full Text PDF

Building a Fast Response Capability for Emerging Infectious Diseases Within the Biomedical Advanced Research and Development Authority.

Health Secur

January 2025

Robert A. Johnson, PhD, is Director, Medical Countermeasures Programs, and Gary L. Disbrow, PhD, is Director, Center for Biomedical Advanced Research and Development Authority (BARDA), Washington, DC. Terence M. Barnhart, PhD, is Senior Strategy Implementation Leader, Tunnell Government Services, Inc. (Contractor Supporting BARDA), Washington, DC.

From influenza to COVID-19, emerging infectious diseases have taken a heavy toll on lives and resources. Emerging infectious diseases represent one of the largest threats to national security. The primary mission of the Center for Biomedical Advanced Research and Development Authority (BARDA), within the US Administration for Strategic Preparedness and Response, is to support the advanced development of medical countermeasures (MCMs) for public health security threats, including select infectious diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!